M&A Deal Summary |
|
|---|---|
| Date | 2017-08-08 |
| Target | Confluence Life Sciences |
| Sector | Life Science |
| Buyer(s) | Aclaris |
| Deal Type | Add-on Acquisition |
| Deal Value | 10M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2012 |
| Sector | Life Science |
| Employees | 61 |
| Revenue | 19M USD (2024) |
Aclaris is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. Aclaris was founded in 2012 and is based in Wayne, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: Missouri M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2017 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-03-28 |
Vixen Pharmaceuticals
United States Vixen Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-10-10 |
RHOFADE
Malvern, Pennsylvania, United States RHOFADE cream is a prescription medicine used on the skin (topical) to treat ongoing facial redness due to rosacea in adults. |
Sell | - |
